Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus (Q39097395)

9 September 2017

Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus (English)

1 reference

9 September 2017

0 references

Alienys Izquierdo

1

1 reference

9 September 2017

Lidice Bernardo

2

1 reference

9 September 2017

Jorge Martin

3

1 reference

9 September 2017

Emidalys Santana

4

1 reference

9 September 2017

Lisset Hermida

5

1 reference

9 September 2017

Gerardo Guillén

6

1 reference

9 September 2017

María G Guzmán

7

1 reference

9 September 2017

4 October 2008

1 reference

9 September 2017

1 reference

9 September 2017

138

1 reference

9 September 2017

1-2

1 reference

9 September 2017

135-138

1 reference

Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates

9 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Flavivirus Type-Specific Antigens Produced from Fusions of a Portion of the E Protein Gene with the Escherichia coli trpe Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Epidemiologic studies on Dengue in Santiago de Cuba, 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Pathogenesis of dengue: challenges to molecular biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Dengue 3 epidemic, Havana, 2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2008.08.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2008.08.008

1 reference

9 September 2017

1 reference